Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB

Infection and Immunity

Volumn 67, Issue 5, 1999, Pages 2552-2560

  Lehmann, A K ^a   Halstensen, A ^a   Aaberge, I S ^b   Holst, J ^b   Michaelsen, T E ^b,c   Sornes S ^a   Wetzler, L M ^d   Guttormsen, H K ^e  

^a UNIVERSITY OF BERGEN   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d BOSTON MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; OPSONIN; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN POR A; OUTER MEMBRANE PROTEIN POR B; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; OXIDATIVE STRESS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RESPIRATORY BURST;

EID: 0032954840     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.5.2552-2560.1999     Document Type: Article

References (50)

1. Aase, A., G. Bjune, E. A. Høiby, E. Rosenqvist, A. K. Pedersen, and T. Michaelsen. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:3531-3536.
2. 1a. Aase, A., E. A. Høiby, and T. Michaelsen. 1998. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47:388-396.
3. 1b. Aase, A., E. A. Høiby, J. Kolberg, E. Rosenqvist, and T. Michaelsen. 1998. Most antibodies to PorB do not bind to viable meningococci, but bind strongly to ethanol-killed bacteria, p. 284. In X. Nassif, M.-J. Quintin-Millet, and M.-K. Taha (ed.), Abstracts of the Eleventh International Pathogenic Neisseria Conference, 1 to 6 November 1999, Nice, France. Editions E.D.K., Paris, France.
4. Aase, A., and T. E. Michaelsen. 1994. Opsonophagocytosis activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand. J. Immunol. 39:581-587.
5. Ala'Aldeen, D. A. A., and E. Griffiths. 1995. Vaccines against meningococcal diseases, p. 1-39. In D. A. A. Ala'Aldeen and C. E. Hormaeche (ed.), Molecular and clinical aspects of bacterial vaccine development. John Wiley & Sons Ltd., Chichester, England.
6. Ala'Aldeen, D. A. A., and K. A. V. Cartwright 1996. Neisseria meningitidis: vaccines and vaccine candidates. J. Infect. 33:153-157.
7. Bjune, G., E. A. Høiby, J. K. Grønnesby, Ø. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A.-K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Frøholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
8. Bredius, R. G. M., B. H. F. Derkx, A. P. Fijen, T. P. M. de Wit, M. de Haas, R. S. Weening, J. G. J. van de Winkel, and T. A. Out. 1994. Fcγ receptor IIa (CD32) polymorphism in fulminant meningococcal shock in children. J. Infect. Dis. 170:848-853.
9. Burton, D. R., L. Gregory, and R. Jefferis. 1986. Aspects of the molecular structure of IgG subclasses. Monogr. Allergy 50:510-516.
10. Ehlenberger, A. G., and V. Nussenzwelg. 1977. The role of membrane receptors for C3b and C3d in phagocytosis. J. Exp. Med. 145:357-371.
11. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4:359-395.
12. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Frøholm, A. K. Lindbak, B. Møgster, E. Namork, U. Rye, G. Stabbetorp R. Winsnes, B. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-80.
13. Fusco, P. C., F. Michon, J. Y. Tai, and M. S. Blake. 1997. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect. Dis. 175:364-372.
14. Griffis, J. M. 1995. Mechanisms of host immunity, p. 35-70. In K. Cartwright (ed.), Meningococcal disease. John Wiley & Sons, Chichester, England.
15. Guttormsen, H.-K., R. Bjerknes, A. Halstensen, A. Næss, E. A. Høiby, and C. O. Solberg. 1993. Cross-reacting serum opsonins to meningococci after vaccination. J. Infect. Dis. 167:1314-1319.
16. Guttormsen, H.-K., R. Bjerknes, A. Næss, V. Lehmann, A. Halstensen, S. Sørnes, and C. O. Solberg. 1992. Cross-reacting serum opsonins in patients with meningococcal disease. Infect. Immun. 60:2777-2783.
17. Guttormsen, H.-K., L. M. Wetzler, and A. Næss. 1993. Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease. Infect. Immun. 61:4734-4742.
18. Guttormsen, H.-K., L. M. Wetzler, and C. O. Solberg. 1994. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect. Immun. 62:1437-1443.
19. Guttormsen, H.-K., L. M. Wetzler, and C. O. Solberg. 1994. Serum opsonins induced during the course of meningococcal disease correlate with anti-outer membrane protein antibodies, p. 54-65. In J. S. Evans, S. E. Yost, M. C. J. Maiden, and I. M. Feavers (ed.), Neisseria 94, Proceedings of the Ninth International Pathogenic Neisseria Conference, 26 to 30 September 1994, Winchester, England.
20. Halstensen, A., H. Sjursen, S. E. Vollset, L. O. Frøholm, A. Næss, R. Matre, and C. O. Solberg. 1989. Serum opsonins to serogroup B meningococci in meningococcal disease. Scand. J. Infect. Dis. 21:267-276.
21. Haneberg, B., R. Dalseg, E. Wedege, E. A. Høiby, I. L. Haugen, F. Oftung, S. R Andersen, L. M. Naess, A. Aase, T. E. Michaelsen, and J. Holst 1998. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66:1334-1341.
22. Hartung, S., E. Rosenqvist, E. A. Høiby, T. W. Gedde-Dahl, and L. O. Frøholm. 1986. Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen. J. Clin. Microbiol. 24:947-953.
23. Høiby, E. A., E. Rosenqvist, L. O. Frøholm, G. Bjune, B. Feiring, H. Nøkleby, and E. Rønnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14:147-155.
24. Kaythy, H., H. Jousimies-Somer, H. Peltota, and P. H. Makela. 1981. Antibody response to capsular polysaccharides of groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J. Infect. Dis. 143:32-41.
25. Kilian, M., J. Mestecky, and M. W. Russell. 1988. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol. Rev. 52:296-303.
26. Lehmann, A. K., A. Halstensen, A. Næss, S. E. Vollset, H. Sjursen, and G. Bjune. 1991. Immunization against serogroup B meningococci. Opsonin response in vaccinees as measured by chemiluminescence. APMIS 99:769-772.
27. Lenmann, A. K., A. Halstensen, J. Holst, and C.-F. Bassøe. 1997. Functional assays for evaluation of serogroup B meningococcal structures as mediators of human opsonophagocytosis. J. Immunol. Methods 200:55-68.
28. Lehmann, A. K., A. Halstensen, and C.-F. Bassøe. 1998. Flowcytometric quantitation of human opsonin-dependent phagocytosis and oxidative burst responses to meningococcal antigens. Cytometry 33:6-13.
29. Lehmann, V., and C. O. Solberg. 1980. Group B meningococcal opsonins in serum measured by polymorphonuclear leukocyte chemiluminescence. APMIS 88:227-231.
30. Mandrell, R. E., and W. D. Zollinger. 1989. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect. Immun. 57:1590-1598.
31. Meyer Næss L., F. Oftung, A. Aase, L. M. Wetzler, R. Sandin, and T. E. Michaelsen. 1998. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. Infect. Immun. 66:959-965.
32. Meyer Næss, L., E. Rosenqvist, E. A. Høiby, and T. E. Michaelsen. 1996. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J. Immunol. Methods 196: 41-49.
33. Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Høiby, E. Rosenqvist, J. Holst, H. Nøkleby, F. Sotolongo, G. Sierra, C. Huergo, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:683-691.
34. Raff, H. V., D. Devereux, W. Shuford, D. Abbot-Brown, and G. Maloney. 1988. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningtidis group B infections. J. Infect. Dis. 157:118-126.
35. Rosenqvist, E., E. A. Høiby, G. Bjune, K. Bryn, O. Closs, B. Feiring, A. Klem, H. Nøkleby, and L. O. Frøholm. 1991. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. NIPH Ann. 14:169-179.
36. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Rønnild, G. Bjune, and H. Nøkleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
37. Ross, G. D. 1989. Complement and complement receptors. Curr. Opin. Immunol. 2:50-62.
38. Ross, S. C., P. J. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155:1266-1275.
39. Rothe, G., A. Oser, and G. Valet. 1988. Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil activity in neutrophil granulocytes. Naturwissenschaften 75:354-355.
40. Schlesinger, M., R. Greenberg, J. Levy, H. Kaythy, and R. Levy. 1994. Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency. J. Infect. Dis. 170:449-453.
41. Sjursen, H., R. Bjerknes, A. Halstensen, A. Næss, L. O. Frøholm, E. Rosenqvist, and C. O. Solberg. 1987. Serum opsonins to group B meningococci. Acta Pathol. Microbiol. Immunol. Scand. 95:283-289.
42. Turner, M., and M. Owen. 1993. Antigen receptor molecules, p. 4.1-4.20. In I. Roitt, J. Brostoff, and D. Male (ed.), Immunology. Mosby-Year Book Europe Limited, London, United Kingdom.
43. Van der Ley, P., and J. T. Poolman. 1992. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60:3156-3161.
44. Van der Voort, E. R., H. van Dijken, B. Kuipers, J. van der Biezen, P. van der Ley, J. Meylis, I. Claassen, and J. Poolman. 1997. Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect. Immun. 65:5184-5190.
45. Van de Winkel, J. G. J., and P. J. A. Capel. 1993. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 14:215-221.
46. Wedege, E., G. Bjune, L. O. Frøholm, E. A. Høiby, and E. Rosenqvist. 1991. Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccine trial. NIPH Ann. 14:183-186.
47. Wedege, E., E. R. van der Voort, B. Kuipers, K. Bolstad, H. van Duken, and J. T. Poolman. 1998. Induced antibody specificities with the Norwegian outer membrane vesicle vaccine in Icelandic teenagers: comparison of bactericidal antibody levels using isogenic strains with specific antibody levels determined by densitometric immunoblot analysis, p. 176. In X. Nassif, M.-J. Quintin-Millet, and M.-K. Taha (ed.), Abstracts of the Eleventh International Pathogenic Neisseria Conference, 1 to 6 November 1998, Nice, France. Editions E.D.K., Paris, France.
48. Wedege, E., E. A. Høiby, E. Rosenqvist, and G. Bjune. 1998. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:3223-3231.
49. Wetzler, L. M., M. S. Blake, K. Barry, and E. C. Gotschlich. 1992. Gonococcal porin evaluation: comparison of por proteosomes, liposomes, and blebs isolated from rmp deletion mutants. J. Infect. Dis. 166:551-555.
50. Zollinger, W. D. 1997. New and improved vaccines against meningococcal disease, p. 469-488. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines. Marcel Dekker, Inc., New York, N.Y.